Target ID & Validation

Target Identification and Validation

Identifying Promising Targets in Early Drug Discovery

  • Easily develop and perform high throughput target ID screens
  • Characterize a wide variety of analytes from small-molecule fragments to biologics

Identifying and characterizing promising therapeutic targets is the first step in the drug discovery process. Validating these targets becomes critical before investing additional time and resources for further development. Label-free binding technologies such as Bio-Layer Interferometry (BLI) and Surface Plasmon Resonance (SPR) systems are indispensable tools in target identification and validation processes where high throughput binding screens can be quickly established. 

Octet® systems are used to identify binding targets and accurately characterize rates of complex formation (ka, association), complex stability (kd, dissociation) and affinities (KD)

Featured Applications

Large Molecules Kinetics Characterization

The Octet® family of instruments accurately measures kinetic constants by bringing the detection surface directly to the sample. This fluidics-free approach to label-free, real-time analysis streamlines laboratory workflows, expedites assay development and allows for direct measurement of crude samples.

Protein - Small Molecules and Peptide Kinetics and Affinity Characterization

In small molecule drug discovery, the path to lead molecules can stem from many starting points including fragment screening or de novo structural design.  Determining and evaluating the affinity of small molecule binding to a therapeutic target is a significant component of the drug discovery process. The hit-to-lead and lead optimization processes are essential to accurately determine biological potency in vitro so structure-activity relationships (SAR) can be used for efficient structural design. The Octet® BLI platform and the Octet® SF3 SPR can be readily used to characterize small molecule and peptide lead candidates where both platforms provide a unique set of advantages from sensitivity, throughput and ready-to-use biosensors to match your workflow needs.

Read Application Note

Fragment Screening

Fragment-based drug design (FBDD) has become an increasingly popular platform for the identification of lead candidates in drug discovery programs. The detection and characterization of fragment binding events is facilitated by sensitive biophysical technologies capable of detecting low-affinity interactions of low molecular weight compounds. The Octet® SF3 system has the necessary sensitivity and throughput to provide complete fragment screens on libraries of several thousand compounds in just a few weeks per target.

Resources

Integrating Octet® BLI into Early Antibody Discovery Workflows

Improve the overall drug discovery process to increase the success rate of preclinical candidates

Watch Webinar
Cross Competition or Epitope Binning Assays on Octet® RH96 System cover image

Cross Competition or Epitope Binning Assays on the Octet® RH96 System

Epitope binning through cross competition assays is a powerful tool in evaluating functional diversity in antibody clones.

Read Application Note

Customized Quantitation of Recombinant Therapeutic Proteins

Using Octet® SAX Biosensors

Read Application Note
A Rapid Method to Quantitatively Screen Bispecific Antibodies Using Protein A and Octet® His1K Biosensors

Screen Bispecific Antibody Using Protein A and His1K Biosensors

Rapid quantitative screening of bispecific antibodies using Protein A and HIS1K biosensors

Read Application Note
Application Note cover

Label-Free Technologies for Accurate Determination of Affinity and Kin...

From target molecule identification to lead selection and optimization, equilibrium affinity and kinetics rate constants are critical parameters in th...

Read Application Note

Streamlining Affinity Analysis for Accelerated Lead Screening

Antibody and other protein therapeutics are a major focus in drug discovery pipelines today. The overall process for developing protein therapeutics e...

Read White Paper

Kinetic Analysis of Antibody Binding to an Expressed Membrane Protein...

Membrane proteins govern the majority of input and output signals of cells and represent the largest class of pharmaceutical drug targets, making the...

Read Application Note

Generating Reliable Kinetic Data for Protein-Ligand Interactions

The Community Structure Activity Resource (CSAR, www.csardock. org) group is developing a database of high quality protein-ligand structures and the c...

Read Application Note

Commitment to Covalency : Kinetics of Irreversible Inhibitors on the P...

The principal role of assay groups in drug discovery is to provide reliable methods, analysis, and data for confident decision-making about series pro...

Read Application Note

Fragment Based Drug Discovery on Pioneer Systems Using Next Generation...

Fragment-based drug design (FBDD) has become an increasingly popular platform for the identification of lead candidates in drug discovery programs.

Read Application Note

OneStep Lead Characterization of High Affinity Biologic Interactions w...

Biopharmaceutical drug discovery and development have celebrated the approval of breakthrough treatments in diseases of inflammation, cancer and infec...

Read Application Note

Reducing Variability in Small Molecule Screening and Kinetics Applicat...

Minimizing the variability of background signals is a key parameter to the success of demanding applications such as small molecule analysis

Read Application Note
Cell Line Development: Accelerating Antibody Discovery by Monitoring Titer and Glycosylation With the Octet® Platform

Application Guide: Cell Line Development

Accelerating Antibody Discovery by Monitoring Titer and Glycosylation With the Octet® Platform

Download Now
Octet® SF3 SPR

Octet® SF3 SPR 

Generate high-quality kinetics and affinity data in a fraction of the time compared to standard multi-cycle kinetics using the Octet® SF3.

Explore Octet® SF3
Octet® BLI rapidly determines recombinant protein concentration as a control parameter in cell line development.

96-Channel Ultra High Throughput Octet System: Octet® RH96

Monitors up to 96 biosensors simultaneously, enabling label-free detection for protein quantitation and kinetic characterization at unmatched speed

Explore Octet® RH96

16-Channel High Throughput Octet System: Octet® RH16

Ideal for high-throughput applications that demand high sensitivity and low sample volume requirements

Explore Octet® RH16

8-Channel System: Octet® R8

Unmatched Flexibility and Versatility in Protein Analysis

Explore Octet® R8

Request a Quote, Demo, or More Information

What other areas are you interested in? (select all that apply)

Request More Information

Related Content

icon-octet-family

Biologics Characterization Tools

Explore More
icon-instrument-service

Octet® System Service and Support

Explore More
icon-supplement

Octet® BLI Resources

Explore More